Network Pharmacology of Atractylodes lancea in Advanced Intrahepatic Cholangiocarcinoma: Integrating Patient Transcriptomics with Molecular Docking

Review History

Published: 2026-11-18

DOI: 10.9734/bpi/psrtc/v3/8227

Page: 60-79


Teerachat Saeheng

Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand and Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand.

Kesara Na-Bangchang *

Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand and Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand and Sakon Nakhon Hospital, Sakon Nakhon Province, Thailand.

*Author to whom correspondence should be addressed.


Abstract

Cholangiocarcinoma (CCA) is an aggressive cancer of the biliary tract associated with a substantial disease burden and a poor prognosis, largely owing to late diagnosis and a limited response to current chemotherapy. Network pharmacology (molecular networking) is a bioinformatic approach that can reveal how complex medicines and new drug candidates act on multiple targets simultaneously. This study applies the approach to Atractylodes lancea (Thunb.) DC. (AL), a botanical candidate for advanced intrahepatic CCA (iCCA), and to its three main bioactive constituents—atractylodin, β-eudesmol and hinesol. Transcriptomic data from a phase IIA clinical trial were used to identify genes whose expression changed in patients treated with AL compared with those receiving standard supportive care, and genes that distinguished progressive from non-progressive disease. A molecular network of AL's signalling pathways was then built in Cytoscape. Fifty-two key target genes were identified. The most highly connected network hubs were TNF (TNF-α), PIK3CA and NRAS, and false discovery rate (FDR) analysis ranked PI3K/AKT signalling, natural killer (NK) cell-mediated cytotoxicity and apoptosis as the three most significantly enriched pathways. In molecular docking, hinesol showed stronger predicted binding to these targets than the other AL constituents and the standard anti-CCA drugs gemcitabine and 5-fluorouracil (5-FU). The work illustrates the value of network analysis for understanding the multi-target action of herbal medicines and links AL to several interconnected pathways of tumour progression, supporting further investigation of its therapeutic potential for advanced iCCA.

Keywords: Atractylodes lancea, cholangiocarcinoma, molecular docking, molecular network, network pharmacology, traditional medicine, transcriptomics


How to Cite

Saeheng, T., & Na-Bangchang, K. (2026). Network Pharmacology of Atractylodes lancea in Advanced Intrahepatic Cholangiocarcinoma: Integrating Patient Transcriptomics with Molecular Docking. Pharmaceutical Science: Research Trends and Challenges Vol. 3, 60–79. https://doi.org/10.9734/bpi/psrtc/v3/8227